BiotechTube

ABT-888

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain Diseases

Conditions

Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Neoplasm Metastasis, Nervous System Neoplasms

Trial Timeline

Mar 1, 2008 → Mar 1, 2013

NCT ID
NCT00649207

About ABT-888

ABT-888 is a phase 1 stage product being developed by AbbVie for Brain Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00649207. Target conditions include Brain Diseases, Brain Neoplasms, Central Nervous System Diseases.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00649207Phase 1Completed

Competing Products

20 competing products in Brain Diseases

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Duloxetine + Sugar pillEli LillyPhase 2
52
Neurosteroid enantiomerOragenicsPhase 2
44
Patritumab deruxtecanDaiichi SankyoPhase 2
52
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
Eribulin MesylateEisaiPhase 1
33
Pembrolizumab + LenvatinibEisaiPhase 2
52
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
52
GLIADELEisaiPhase 2
52
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
33
abemaciclib + abemaciclibEli LillyPhase 2
52
JNJ-17299425Johnson & JohnsonPhase 2
52
Veliparib + PlaceboAbbViePhase 2
52
Iressa (Gefitinib)AstraZenecaPhase 2
52
Trastuzumab deruxtecanAstraZenecaPhase 2
52
ExenatideAstraZenecaApproved
85
AZD5213AstraZenecaPhase 1
33
VorinostatMerckPhase 1
33

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85